Abstract

BackgroundMost of the currently available biological agents used in the treatment of rheumatoid arthritis (RA) target a cellular or soluble factor involved in the physiopathology of the disease. Alternatively, cellular...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Apoptotic cell-based therapy to treat collagen-induced experimental arthritis (P5191)
Philippe Saas ... Sylvain Perruche
The Journal of Immunology | VOL. 190
Philippe Saas, et. al.Philippe Saas ... Sylvain Perruche
01 May 2013
SAT0046 Regulation of Sirt1 Maybe A Pioneering Strategy in Treatment of Rheumatoid Arthritis
...
Annals of the Rheumatic Diseases | VOL. 75
, et. al. ...
01 Jun 2016
Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets.
Yajie Zhang ... Chunhua Ma
Frontiers in immunology | VOL. 9
Yajie Zhang, et. al.Yajie Zhang ... Chunhua Ma
26 Sep 2018
Rituximab exerts its anti-arthritic effects via inhibiting NF-κB/GM-CSF/iNOS signaling in B cells in a mouse model of collagen-induced arthritis
Mohammed A Al-Hamamah ... Sheikh F Ahmad
Heliyon | VOL. 9
Mohammed A Al-Hamamah, et. al.Mohammed A Al-Hamamah ... Sheikh F Ahmad
25 May 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers